+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


pharmahandbook: Three Report Special Offer - BRIC/Asia Pacific/United States

  • ID: 2755024
  • Book
  • July 2013
  • Region: China, United States, India, Asia Pacific, Brazil, Russia
  • 595 Pages
  • VOI Consulting, Inc
1 of 1
Asia-Pacific 2013: 260-page report with what you need to know to succeed in 8 key pharma markets with $300 billion in combined sales.

Intellectual property in India. PBS access in Australia. Generics in Japan. And China. What about China? The pharmaceutical industry has questions. Our Asia-Pacific report has answers. It contains the information and analysis you need to expand or improve your drug development and business prospects in 8 countries with 55% of the world's population and $300 billion in combined pharmaceutical sales. The world's second and third-largest markets, Japan and China, are covered as are rapidly-developing India and Indonesia, newly-emerged South Korea and Taiwan, and mature but still-evolving Australia and New Zealand.

BRIC Report 2013: 175-pages packed with data and analysis on structural, regulatory and commercial aspects in each of pharma's Big 4 emerging markets: Brazil, Russia, India, and China.

Brazil, Russia, India, China. They share an acronym and rapid growth rates but otherwise the Big 4 Emerging Markets don't have a lot in common. With extensive data and analysis on the structural, regulatory and commercial aspects of the biopharmaceutical markets in each country, pharmahandbook's 2013 BRIC report provides you with what you need to know in order to capitalize on these vitally important but complex and differentiated opportunities.

United States 2013: 160-page report with in-depth coverage of virtually every aspect of the world's largest pharmaceutical market. The most thorough and incisive report on navigating the U.S. pharma market available.

$325 billion. That's the size of the U.S. pharmaceutical market. It translates to one-third of global industry sales but achieving success in the world's largest market is a lot tougher than it used to be. That's where the latest U.S. pharmahandbook comes in. If you want to understand how the Affordable Care Act will affect your sales, where the brand and generic sectors will be in five years, what's happening with biosimilars, how the pricing and reimbursement systems are changing, and the real reason that pharmaceuticals sales have slowed (as well as what you can do about it), look no further than U.S. pharmahandbook 2013.

About this report

An “essential resource”, "invaluable", "extremely useful", "a wonderful source of information"…that's what customers in the international pharmaceutical industry have been saying about pharmahandbook since 2003.

Why you need it

The markets are essential for any pharmaceutical company that hopes to grow its business over the next five years. This pharmahandbook report shows you how to succeed in these important and challenging locations.
Note: Product cover images may vary from those shown